Assess the unmet treatment needs in patients with gMG and the rationale for integrating targeted therapies into management. Summarize the contribution of B and T cells in the pathogenesis of MG and how novel biologic therapies target these mechanisms. Describe the contribution of complement and FcRn in the pathogenesis of MG and how novel biologic therapies target these pathways.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
89% of listed courses are free
25 of 28 courses listed here are free.
Collected from the provider’s public pages · source
Specialties served/covered
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Cardiothoracic Surgery
- Critical Care Medicine
- Endocrinology, Diabetes & Metabolism
- Gastroenterology
- Gastrointestinal Surgery
- General Surgery
- Gynecologic Oncology
- Head & Neck Surgery
- Hematology
- Medical Genetics & Genomics
- Medical Oncology
- Neurology
- Neuromuscular Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Orthopaedic Surgery
- Orthopaedic Trauma
- Pulmonary Disease
- Surgical Critical Care
- Surgical Oncology
- Thoracic Surgery
- Cardio-Vascular
- Emergency & Critical Care
- ENT & Head Neck
- GI & Liver
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Orthopedics
- Pathology & Lab
- Surgery
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Enduring / On-demand
- Credit · Up to 1 credit
- Commercial Support
-
ReleasedJul 9, 2026
-
Last day to claim creditJul 10, 2027 9 months left
-
Haymarket Medical Education Integrating FcRn and Complement System Therapies for Generalized Myasthenia Gravis
-
The Guthy-Jackson Charitable Foundation (GJCF) +1 Pathogenesis & Immunologic Targets
-
Clinical Care Options, LLC (dba Decera Clinical Education) Mechanism Matters in gMG: Why Complement and FcRn Are Reshaping Treatment Conversations
-
touchIME, USF Health Optimizing outcomes in advanced endometrial carcinoma: Navigating guidelines, biomarker-driven immunotherapy and irAE management
-
touchIME, USF Health Breakthroughs in Treating NSCLC: Targeting RAS
-
touchIME, USF Health Where we are now in PDAC care: Clinical insights, emerging biomarkers and evolving therapeutic strategies
